GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Cyclically Adjusted Revenue per Share

Rosetta Genomics (Rosetta Genomics) Cyclically Adjusted Revenue per Share : $0.00 (As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rosetta Genomics's adjusted revenue per share for the three months ended in Jun. 2017 was $0.342. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jun. 2017.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-25), Rosetta Genomics's current stock price is $0.0001. Rosetta Genomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2017 was $0.00. Rosetta Genomics's Cyclically Adjusted PS Ratio of today is .


Rosetta Genomics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Rosetta Genomics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Cyclically Adjusted Revenue per Share Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rosetta Genomics's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Rosetta Genomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Cyclically Adjusted PS Ratio falls into.



Rosetta Genomics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rosetta Genomics's adjusted Revenue per Share data for the three months ended in Jun. 2017 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=0.342/103.3491*103.3491
=0.342

Current CPI (Jun. 2017) = 103.3491.

Rosetta Genomics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200512 0.000 83.032 0.000
200603 0.000 84.298 0.000
200606 0.000 85.606 0.000
200609 0.000 85.606 0.000
200612 0.000 85.142 0.000
200703 0.000 86.640 0.000
200706 0.000 87.906 0.000
200709 0.000 87.964 0.000
200712 0.000 88.616 0.000
200803 0.000 90.090 0.000
200806 0.000 92.320 0.000
200809 0.000 92.307 0.000
200812 -41.471 88.697 -48.321
200903 1.000 89.744 1.152
200906 0.737 91.003 0.837
200909 0.000 91.120 0.000
200912 5.950 91.111 6.749
201003 1.174 91.821 1.321
201006 3.043 91.962 3.420
201009 5.913 92.162 6.631
201012 1.840 92.474 2.056
201103 1.121 94.283 1.229
201106 0.524 95.235 0.569
201112 0.000 95.213 0.000
201206 0.000 96.819 0.000
201212 0.000 96.871 0.000
201306 0.000 98.518 0.000
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 0.283 100.428 0.291
201412 0.510 99.070 0.532
201503 0.302 99.621 0.313
201506 1.628 100.684 1.671
201509 1.976 100.392 2.034
201512 2.081 99.792 2.155
201603 1.512 100.470 1.555
201606 0.232 101.688 0.236
201609 1.265 101.861 1.283
201612 1.095 101.863 1.111
201706 0.342 103.349 0.342

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Rosetta Genomics  (OTCPK:ROSGQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rosetta Genomics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458